Concord Biotech (CONCORDBIO) Q4 24/25 earnings summary

Executive summary

• Achieved consolidated revenue of ₹1,200.1 Cr in FY25, up 18% year-over-year, with Q4FY25 revenue at ₹429.9 Cr, up 35% from Q4FY24.

• PAT increased 21% to ₹371.6 Cr in FY25, with Q4 PAT up 48% to ₹140.4 Cr, reflecting strong operational performance.

• Strategic investments made in Palwela/Palvella Therapeutics (rare skin diseases) and CleanMax (renewable energy) to support growth and ESG goals.

• Commissioned a new injectable facility and expanded product pipeline in APIs and formulations, with key regulatory approvals supporting global expansion.

• Audited standalone and consolidated financial results for FY25 were approved, with auditors issuing unmodified opinions.

Financial highlights

• FY25 revenue: ₹1,200.1 Cr (up 18% YoY); Q4FY25 revenue: ₹429.9 Cr (up 35% YoY).

• FY25 PAT: ₹371.6 Cr (up 21% YoY); Q4FY25 PAT: ₹140.4 Cr (up 48% YoY).

• FY25 EBITDA: ₹506.3 Cr (up 17% YoY); Q4FY25 EBITDA: ₹190.4 Cr (up 42% YoY).

• FY25 EBITDA margin: 42.2%; PAT margin: 31.0%; gross profit margin: 74.5%.

• EPS for FY25 at ₹35.5, up from ₹29.4 in FY24.

Outlook and guidance

• Well positioned for accelerated growth, leveraging a broad API and formulation portfolio and new injectable capacity.

• No specific FY26 guidance; long-term CAGR target of 25% with gradual progression from current 18%.

• CDMO business expected to become a double-digit contributor to sales in the next few years.

• Focus on scaling domestic and global presence, investing in R&D, and expanding product pipeline.

• Continued emphasis on innovation, operational efficiency, and sustainable value creation.